ProKidney finalizes separation agreement with ex-CEO Bertram; $620K severance plus benefits

PROKIDNEY CORP.

Company pays $620K severance, bonus up to 60% of base salary for 2023 based on scorecard.
COBRA/Medicare premiums paid 100% through May 31, 2025; legal fees reimbursed up to $20K.
Vested stock options exercisable for 90 days after effective date; unvested equity forfeited.
Vested Class B ordinary shares remain subject to lockup until July 11, 2026 or regulatory milestone.
Standard release, non-disparagement, cooperation, and continuing obligations included.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Dr. Bertram

Ceo

PROK · PROKIDNEY CORP.

Effective: 2024-03-13
Filed: March 18, 2024, 7:59 PM ET

On March 13, 2024 (the “Effective Date”), the Company entered into a Separation Agreement (the “Separation Agreement”) with Dr. Bertram.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.65

Dr. Bertram departed as ceo at PROKIDNEY CORP..

Action: separated

Exact text from the filing

On March 13, 2024 (the “Effective Date”), the Company entered into a Separation Agreement (the “Separation Agreement”) with Dr. Bertram.

View on SEC.gov

PROKIDNEY CORP. filing history →

Source: SEC EDGAR

accession 0000950170-24-032821

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.